SINGAPORE – US-based pharmaceutical company, Catalent has invested US$2.2 million to expand its clinical supply facility in Singapore.
The investment will increase the site’s footprint by nearly 20%, to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature storage.
The expansion will also include the addition of specialized secondary packaging capabilities for ULT products, enabling the site’s services to support larger packaging campaigns, and increasing capabilities to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines, and cell and gene therapies.
“Our Singapore site serves as a strategic supply hub for the Asia-Pacific market, offering a wide range of services to customers in over 20 countries in the region,” said Roel de Nobel, Catalent’s Vice President and General Manager, APAC, Clinical Development & Supply.
“As the site prepares to mark its 25-year anniversary, this is the latest in a series of investments and expansions that it has undertaken to meet the increasing and diversified demands of customers in its mission to develop life-changing medicines for both the region and the world.”
Catalent’s site in Singapore, in addition to its locations in China and Japan, provides a wide range of clinical supply services to the Asia-Pacific region.
The services include clinical supply management, comparator sourcing, Catalent’s FastChain demand-led supply solution, secondary packaging, storage, and international distribution, as well as clinical returns and destruction.
For more than a year and through a leadership change, Catalent has been focused on growth.
Last month the company completed the acquisition of Metrics Contract Services in a deal worth US$475 million.
The acquisition will bolster Catalent’s capabilities in integrated oral solid formulation development, manufacturing and packaging to help customers simplify and accelerate their program.
The company, a subsidiary of Australia-based Mayne Pharma Group, has a 333,000-square-foot plant in Greenville, N.C., with the capacity to produce more than 1 billion solid-dose pills annually.
Catalent also upgraded the primary packaging capabilities of its clinical supply facility in Shiga, Japan in June this year. It installed a high-speed blister packaging line.
The line is similar to those installed at other Catalent clinical supply facilities and will complement the Shiga plant’s existing automated bottling line.
Over the last 13 months, the company has spent more than US$1 billion on a variety of acquisitions.
Liked this article? Subscribe to our regular email newsletters with the latest news insights from Africa and the World’s packaging and printing industry. SUBSCRIBE HERE.
